e-learning
resources
Stockholm 2002
Tuesday 17.09.2002
Management of tuberculosis in adults and children
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Treatment efficacy of MDR TB based on drug susceptibility testing with microchip technology
I. A. Vassilieva, L. N. Tchernousova (Moscow, Russia)
Source:
Annual Congress 2002 - Management of tuberculosis in adults and children
Session:
Management of tuberculosis in adults and children
Session type:
Oral Presentation
Number:
3513
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. A. Vassilieva, L. N. Tchernousova (Moscow, Russia). Treatment efficacy of MDR TB based on drug susceptibility testing with microchip technology. Eur Respir J 2002; 20: Suppl. 38, 3513
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Related content which might interest you:
The impact and cost-effectiveness of strategies to detect drug-resistant tuberculosis
Source: Eur Respir J 2012; 39: 626-634
Year: 2012
Treatment outcome of multi drug resistant tuberculosis patients in modified DOTS-PLUS: A new strategy
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012
Treatment outcome of multi drug resistant tuberculosis patients in modified DOTS-PLUS: A new strategy
Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis
Year: 2011
Evaluation of the microscopic observation drug susceptibility assay for the detection of first- and second-line drug susceptibility for Mycobacterium tuberculosis
Source: Eur Respir J , 49 (4) 1602215; DOI: 10.1183/13993003.02215-2016
Year: 2017
Second-line anti-tuberculosis drug concentrations for susceptibility testing in the MODS assay
Source: Eur Respir J 2013; 41: 1163-1171
Year: 2013
The effectiveness of the introduction of the updated treatment regimens and microbiological diagnostics MDR/XDR tuberculosis
Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II
Year: 2019
Representative drug susceptibility patterns for guiding design of retreatment regimens for MDR – TB in Iran
Source: Annual Congress 2007 - Specific problems in caring for multidrug-resistant tuberculosis and tuberculosis/HIV cases
Year: 2007
Evaluation the drug susceptibility testing and the prevalence of resistance to antituberculosis drugs in a chronic department
Source: Eur Respir J 2003; 22: Suppl. 45, 520s
Year: 2003
Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis
Source: Eur Respir J , 49 (4) 1700317; DOI: 10.1183/13993003.00317-2017
Year: 2017
Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis
Source: Eur Respir J , 49 (4) 1700173; DOI: 10.1183/13993003.00173-2017
Year: 2017
Rational use of tuberculosis drugs to prevent the development of drug resistance
Source: Annual Congress 2012 - MDR- and XDR-TB: epidemiological and public health overview
Year: 2012
Our experience in multi drug resistant tuberculosis (MDR TB) treatment
Source: Eur Respir J 2005; 26: Suppl. 49, 652s
Year: 2005
Application of next-generation sequencing to detect MTB resistance to first- and second-line anti-TB drugs
Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis
Year: 2020
Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB
Source: Eur Respir J 2009; 33: 581-585
Year: 2009
Treatment out-come in acquired drug resistance tuberculous patients receiving tailored regimen based on sensitivity report
Source: Annual Congress 2008 - Outcomes of tuberculosis treatment
Year: 2008
Availability of drug susceptibility testing to new/re-purposed anti-tuberculosis drugs: a TBnet study
Source: Virtual Congress 2021 – Advances in the diagnosis of tuberculosis, multidrug-resistant tuberculosis and nontuberculous mycobacterial disease
Year: 2021
Outcome of drug resistant TB in hospital settings-a comparision of individualized treatment based on past history of anti-TB drugs with culture sensitivity guided treatment
Source: Eur Respir J 2006; 28: Suppl. 50, 589s
Year: 2006
The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection
Source: Eur Respir J 2015; 45: 569-571
Year: 2015
The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection
Source: Eur Respir J 2015; 45: 571-574
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept